X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (162) 162
Conference Proceeding (83) 83
Book Review (20) 20
Publication (8) 8
Book / eBook (6) 6
Book Chapter (5) 5
Web Resource (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hematology (116) 116
humans (104) 104
index medicus (101) 101
oncology (92) 92
male (64) 64
female (63) 63
adult (60) 60
middle aged (59) 59
aged (49) 49
antineoplastic combined chemotherapy protocols - therapeutic use (41) 41
treatment outcome (33) 33
chemotherapy (32) 32
transplantation (32) 32
prognosis (30) 30
non-hodgkins-lymphoma (23) 23
adolescent (22) 22
lymphomas (20) 20
immunology (19) 19
therapy (19) 19
antineoplastic combined chemotherapy protocols - adverse effects (18) 18
combined modality therapy (18) 18
disease-free survival (18) 18
lymphoma (17) 17
retrospective studies (17) 17
transplantation, autologous (17) 17
care and treatment (16) 16
recurrence (16) 16
rituximab (15) 15
cyclophosphamide - administration & dosage (14) 14
hematopoietic stem cell transplantation (14) 14
aged, 80 and over (13) 13
cancer (13) 13
medicine, research & experimental (13) 13
research (13) 13
survival rate (13) 13
doxorubicin - administration & dosage (12) 12
high-dose therapy (12) 12
follow-up studies (11) 11
lymphoma, non-hodgkin - drug therapy (11) 11
neoplasm staging (11) 11
remission induction (11) 11
stem cells (11) 11
survival analysis (11) 11
bone-marrow transplantation (10) 10
combination chemotherapy (10) 10
cyclophosphamide (10) 10
etoposide - administration & dosage (10) 10
health aspects (10) 10
antineoplastic agents - therapeutic use (9) 9
antineoplastic combined chemotherapy protocols - administration & dosage (9) 9
disease (9) 9
hematopoietic stem cell transplantation - methods (9) 9
lymphoma, non-hodgkin - therapy (9) 9
survival (9) 9
vincristine - administration & dosage (9) 9
abridged index medicus (8) 8
bone-marrow-transplantation (8) 8
hodgkin disease - drug therapy (8) 8
hodgkin disease - therapy (8) 8
relapse (8) 8
treatment (8) 8
young adult (8) 8
diagnosis (7) 7
disease progression (7) 7
diseases (7) 7
etoposide (7) 7
hodgkin disease - pathology (7) 7
leukemia (7) 7
lymphoma - therapy (7) 7
lymphoma, non-hodgkin - pathology (7) 7
methods (7) 7
prospective studies (7) 7
risk factors (7) 7
salvage therapy (7) 7
stem-cell transplantation (7) 7
acute myeloid-leukemia (6) 6
antibodies, monoclonal - therapeutic use (6) 6
antibodies, monoclonal, murine-derived (6) 6
b-cell lymphoma (6) 6
child (6) 6
classification (6) 6
follicular lymphoma (6) 6
hematology, oncology and palliative medicine (6) 6
hematopoietic stem cells (6) 6
hodgkin's disease (6) 6
k ma hematology (6) 6
lymphoma, large b-cell, diffuse - mortality (6) 6
lymphoma, large b-cell, diffuse - pathology (6) 6
lymphoma, non-hodgkin - mortality (6) 6
neoplasms - therapy (6) 6
non-hodgkin's lymphoma (6) 6
prednisone - administration & dosage (6) 6
risk (6) 6
transplantation, homologous (6) 6
trial (6) 6
1st complete remission (5) 5
abvd (5) 5
analysis (5) 5
antineoplastic agents - adverse effects (5) 5
bleomycin - administration & dosage (5) 5
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
Online Resources - Online (2) 2
Robarts - Stacks (2) 2
Scarborough Hospital - Online (2) 2
Gerstein Science - Stacks (1) 1
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
Providence Healthcare - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2012, Emerging cancer therapeutics, ISBN 9781617051319, Volume 3, issue 2
Book
2014, Second edition., Cambridge medicine, ISBN 9781107010598, xi, 311 pages
Major advances have occurred in the diagnosis and treatment of lymphoma in recent years. Our understanding of the molecular biology and genetics of the disease... 
diagnosis | physiopathology | Lymphoma | therapy | Pictorial works | Lymphomas | Treatment | Diagnosis
Book
2012, Emerging cancer therapeutics, ISBN 9781617051319, Volume 3, issue 2
Web Resource
Blood, ISSN 0006-4971, 06/2015, Volume 125, Issue 24, pp. 3673 - 3674
In this issue of Blood, Kurtz et al report the potential clinical utility of immunoglobulin high-throughput sequencing as a tool for disease monitoring and... 
CT SCANS | NON-HODGKIN-LYMPHOMA | THERAPY | HEMATOLOGY | Female | Male | Immunoglobulins - genetics | Lymphoma, Large B-Cell, Diffuse - pathology | Lymphoma, Large B-Cell, Diffuse - genetics | Humans | Index Medicus | Abridged Index Medicus
Journal Article
ONCOLOGY-NEW YORK, ISSN 0890-9091, 05/2019, Volume 33, Issue 5, pp. 194 - 194
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2016, Volume 34, Issue 17, pp. 2020 - 2027
Journal Article
Blood, ISSN 0006-4971, 04/2010, Volume 115, Issue 13, pp. 2578 - 2585
Certain malignant B cells rely on B-cell receptor (BCR)-mediated survival signals. Spleen tyrosine kinase (Syk) initiates and amplifies the BCR signal. In in... 
RHEUMATOID-ARTHRITIS | BCR | B-CELL LYMPHOMA | RESPONSE CRITERIA | R-CHOP | THERAPEUTIC TARGET | PHASE-III | TYROSINE KINASE INHIBITOR | FOLLICULAR LYMPHOMA | HEMATOLOGY | EXPRESSION | Humans | Middle Aged | Neoplasm Proteins - physiology | Salvage Therapy | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Lymphoma, Non-Hodgkin - enzymology | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Protein-Tyrosine Kinases - physiology | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Oxazines - administration & dosage | Syk Kinase | Lymphoma, Non-Hodgkin - drug therapy | Oxazines - pharmacology | Pyridines - therapeutic use | Hematologic Diseases - chemically induced | Pyridines - administration & dosage | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Treatment Outcome | Oxazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - enzymology | Oxazines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Intracellular Signaling Peptides and Proteins - physiology | Cohort Studies | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
2007, ISBN 0521865441, xiv, 277
Major advances have occurred in almost every aspect of the diagnosis and treatment of lymphoma in recent years. Our understanding of the molecular biology and... 
Lymphoma
Book
British Journal of Haematology, ISSN 0007-1048, 09/2015, Volume 170, Issue 5, pp. 669 - 678
The oral BCL 2 inhibitor navitoclax has moderate single‐agent efficacy in chronic lymphocytic leukaemia ( CLL ) and minor activity in lymphoma in Phase 1... 
BCL | navitoclax | B‐cell malignancy | rituximab | BCL2 | Rituximab | Navitoclax | B-cell malignancy | CYCLOPHOSPHAMIDE | CHEMOTHERAPY PLUS RITUXIMAB | B-CELL LYMPHOMA | ANTI-CD20 MONOCLONAL-ANTIBODY | INTERNATIONAL WORKSHOP | IDEC-C2B8 | VINCRISTINE | CHRONIC LYMPHOCYTIC-LEUKEMIA | CHOP | LOW-GRADE | HEMATOLOGY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Lymphoma, Follicular - blood | Aged, 80 and over | Adult | Female | Leukemia, Lymphocytic, Chronic, B-Cell - blood | Aniline Compounds - administration & dosage | Antigens, CD20 | Antibodies, Monoclonal, Murine-Derived - pharmacokinetics | Aniline Compounds - pharmacokinetics | Sulfonamides - pharmacokinetics | Sulfonamides - adverse effects | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Aniline Compounds - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Care and treatment | Relapse | Safety and security measures | Analysis | Leukemia | Lymphomas | Antineoplastic agents | Diseases | Index Medicus
Journal Article
2008, Fast facts, ISBN 9781903734995
Web Resource
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 03/2017, Volume 35, Issue 8, pp. 229 - 229
Conference Proceeding
Journal Article
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.